HomeCompareLOKB vs ABBV

LOKB vs ABBV: Dividend Comparison 2026

LOKB yields 14.95% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $49.0K in total portfolio value· pulled ahead in Year 7
10 years
LOKB
LOKB
● Live price
14.95%
Share price
$13.38
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$53.3K
Annual income
$3,763.60
Full LOKB calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — LOKB vs ABBV

📍 ABBV pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLOKBABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LOKB + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LOKB pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LOKB
Annual income on $10K today (after 15% tax)
$1,270.55/yr
After 10yr DRIP, annual income (after tax)
$3,199.06/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $17,856.94/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LOKB + ABBV for your $10,000?

LOKB: 50%ABBV: 50%
100% ABBV50/50100% LOKB
Portfolio after 10yr
$77.8K
Annual income
$14,267.68/yr
Blended yield
18.34%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

LOKB
No analyst data
Altman Z
21.8
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LOKB buys
0
ABBV buys
0
No recent congressional trades found for LOKB or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLOKBABBV
Forward yield14.95%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$53.3K$102.3K
Annual income after 10y$3,763.60$24,771.77
Total dividends collected$25.7K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: LOKB vs ABBV ($10,000, DRIP)

YearLOKB PortfolioLOKB Income/yrABBV PortfolioABBV Income/yrGap
1$12,195$1,494.77$11,550$430.00+$645.00LOKB
2$14,752$1,703.58$13,472$627.96+$1.3KLOKB
3$17,711$1,926.00$15,906$926.08+$1.8KLOKB
4$21,111$2,161.01$19,071$1,382.55+$2.0KLOKB
5$24,997$2,407.44$23,302$2,095.81+$1.7KLOKB
6$29,410$2,664.01$29,150$3,237.93+$260.00LOKB
7← crossover$34,398$2,929.36$37,536$5,121.41$3.1KABBV
8$40,008$3,202.04$50,079$8,338.38$10.1KABBV
9$46,290$3,480.61$69,753$14,065.80$23.5KABBV
10$53,293$3,763.60$102,337$24,771.77$49.0KABBV

LOKB vs ABBV: Complete Analysis 2026

LOKBStock

Live Oak Acquisition Corp. II is a blank check company. The company was founded in 2020 and is based in Memphis, Tennessee.

Full LOKB Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this LOKB vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LOKB vs SCHDLOKB vs JEPILOKB vs OLOKB vs KOLOKB vs MAINLOKB vs JNJLOKB vs MRKLOKB vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.